文献速递免疫规划卫生政策与健康促进

低收入和中等收入国家流感免疫规划的数据与产品需求:WHO下一代流感疫苗首选产品特性的理由与主要结论

Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines.
PubMed 文献 · Vaccine · 2017-09-20

2017年WHO召集全球专家工作组制定下一代流感疫苗首选产品特性(PPC),以鼓励疫苗创新并反映WHO促进高公共卫生影响且适合低收入和中等收入国家(LMIC)的疫苗开发使命。工作组认为现有流感疫苗不适合LMIC使用,并强调新流感疫苗需提供更好数据以证明其在LMIC的价值。

要点

  • WHO PPC描述疫苗的适应症、目标人群、实施策略及评估安全性和有效性所需的临床数据。
  • 工作组认为现有流感疫苗不适合LMIC使用,因健康系统难以向成人和老年人交付疫苗。
  • LMIC决策者可能更重视预防严重疾病的疫苗,而临床开发聚焦于预防任何流感疾病。

核心结论

  • 现有流感疫苗不适合LMIC使用,新流感疫苗需提供更好数据以证明其在LMIC的价值。

研究设计与样本

  • 2017年WHO召集全球专家工作组制定下一代流感疫苗PPC。

主要发现

  • 许多发达国家的制造商和研究资助者优先考虑用于成人和老年人的流感疫苗产品,而大多数LMIC没有足够强大的卫生系统向这些群体提供疫苗。
  • LMIC决策者可能更重视预防严重疾病的疫苗,但流感疫苗的临床开发聚焦于证明预防任何流感疾病。
  • 许多流感疫苗产品不符合WHO的疫苗规划适宜性标准,在低资源环境中使用面临挑战。
  • 当前疫苗与LMIC常规免疫规划整合不佳,原因包括疫苗许可年龄、为温带国家市场设定的任意有效期以及流感季节性延长国家需全年免疫。

临床怎么用

  • 所有感兴趣的各方应参考完整的PPC文件了解细节,本文重点介绍新流感疫苗的数据需求以更好证明其在LMIC的价值主张。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2017, WHO convened a working group of global experts to develop the Preferred Product Characteristics (PPC) for Next-Generation Influenza Vaccines. PPCs are intended to encourage innovation in vaccine development. They describe WHO preferences for parameters of vaccines, in particular their indications, target groups, implementation strategies, and clinical data needed for assessment of safety and efficacy. PPCs are shaped by the global unmet public health need in a priority disease area for which WHO encourages vaccine development. These preferences reflect WHO's mandate to promote the development of vaccines with high public health impact and suitability in Low- and Middle-Income Countries (LMIC). The target audience is all entities intending to develop or to achieve widespread adoption of a specific influenza vaccine product in these settings. The working group determined that existing influenza vaccines are not well suited for LMIC use. While many developed country manufactures and research funders prioritize influenza vaccine products for use in adults and the elderly, most LMICs do not have sufficiently strong health systems to deliver vaccines to these groups. Policy makers from LMICs are expected to place higher value on vaccines indicated for prevention of severe illness, however the clinical development of influenza vaccines focuses on demonstrating prevention of any influenza illness. Many influenza vaccine products do not meet WHO standards for programmatic suitability of vaccines, which introduces challenges when vaccines are used in low-resource settings. And finally, current vaccines do not integrate well with routine immunization programs in LMICs, given age of vaccine licensure, arbitrary expiration dates timed for temperate country markets, and the need for year-round immunization in countries with prolonged influenza seasonality. While all interested parties should refer to the full PPC document for details, in this article we highlight data needs for new influenza vaccines to better demonstrate the value proposition in LMICs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Neuzil KM, Bresee JS, de la Hoz F, et al. Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines. Vaccine. 2017. PMID: 28893473. doi:10.1016/j.vaccine.2017.08.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。